Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer
Status
Conditions
Treatments
Details and patient eligibility
About
Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China.
Full description
Pepsinogens (PGs) can be used for gastric cancer (GC) screening, but the cutoff levels vary among studies, and PG levels are influenced by numerous factors. To examine the diagnostic value of PG levels and Helicobacter pylori (Hp) status for GC and precancerous lesions screening in asymptomatic individuals undergoing health checkup in China. We operated a multicenter cross-sectional study of subjects who underwent health checkup at nine International Healthcare Centers in China. All participants underwent gastroscopy and pathological examination, serum PG, 13C-urea breath test, and/or Hp serological current infection marker rapid test, all on the same day. PG related parameters were analyzed in different Hp subgroups and regions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
intention to undergo gastroscopy during health checkup examination 25-75 years of age.
Exclusion criteria
a history of gastric ulcer, gastric polyp, or GC a history of gastrectomy treatment with a proton pump inhibitor in the last month contraindications to gastroscopy a history of Hp eradication a history of abdominal pain, abdominal distention, belching, acid reflux, nausea and other digestive tract symptoms within 1 month incomplete data.
Trial design
5,000 participants in 4 patient groups
Trial contacts and locations
Loading...
Central trial contact
Yuling Tong, Dr.; Zhenya Song, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal